Register Login

Abiopharma

  • Home
  • About
  • Newsroom
  • Company List
  • Events
  • Automated Tools
  • Contact

News list

ALIBABA GROUP HOLDING LTD (BABA)

  • Business News
  • June 29, 2026, 11:40 UTC
  • 4
  • 1 comments

Alibaba Group Holding Limited Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – BABA

Market reaction Comment Full text

CYBIN INC. (HELP)

  • Business News
  • June 29, 2026, 11:40 UTC
  • 4
  • 1 comments

Helus Pharma Reports Recent Business Highlights and Fiscal Year 2026 Financial Results

Market reaction Comment Full text

ACROMETA GROUP LIMITED (LQPR)

  • Business News
  • June 29, 2026, 11:39 UTC
  • 2
  • 0 comments

Disclosure of Interest/ Changes in Interest of Director/ Chief Executive Officer: Change in Interest of Director - Mahtani Bhagwandas

Market reaction Comment Full text

ACROMETA GROUP LIMITED (LQPR)

  • Business News
  • June 29, 2026, 11:39 UTC
  • 2
  • 0 comments

Disclosure of Interest/ Changes in Interest of Director/ Chief Executive Officer: Change in Interest of Director - Toh Ker How

Market reaction Comment Full text

NAM CHEONG LIMITED (1MZ)

  • Business News
  • June 29, 2026, 11:35 UTC
  • 2
  • 0 comments

General Announcement: INCORPORATION OF NEW SUBSIDIARY IN THE UNITED ARAB EMIRATES

Market reaction Comment Full text

Brainsway Ltd (BWAY)

  • Business News
  • June 29, 2026, 11:30 UTC
  • 4
  • 1 comments

BrainsWay Presents Positive Data from Largest Real-World Study of Deep TMS™ in Patients with Comorbid PTSD and Major Depressive Disorder

Market reaction Comment Full text

BRAINSWAY LTD. (BWAY)

  • Business News
  • June 29, 2026, 11:30 UTC
  • 4
  • 1 comments

BrainsWay Presents Positive Data from Largest Real-World Study of Deep TMS™ in Patients with Comorbid PTSD and Major Depressive Disorder

Market reaction Comment Full text

Biohaven Pharmaceutical Holding Company Ltd. (BHVN)

  • Business News
  • June 29, 2026, 11:30 UTC
  • 3
  • 1 comments

Biohaven Advances a New Class of Precision Immunology Therapies: First MoDE Extracellular Protein Degrader, BHV-1300, Begins Phase 3 Pivotal Trial in Graves' Disease

Market reaction Comment Full text

ZURA BIO LTD (ZURA)

  • Business News
  • June 29, 2026, 11:30 UTC
  • 4
  • 1 comments

Zura Bio Exceeds Enrollment Target in Both Hidradenitis Suppurativa (HS) & Systemic Sclerosis (SSc) Phase 2 Studies and Expands Tibulizumab Program

Market reaction Comment Full text

PALVELLA THERAPEUTICS, INC. (PVLA)

  • Business News
  • June 29, 2026, 11:30 UTC
  • 4
  • 1 comments

Palvella Therapeutics Submits First Module of Rolling New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations

Market reaction Comment Full text
  • Previous
  • 4208
  • 4209
  • 4210
  • 4211
  • 4212
  • Next

Search

News categories

  • Technical Exchange News(14802)
  • Event(6229)
  • SEC News(399156)
  • FDA Approval(10304)
  • Company Report(721)
  • Business News(243581)
Market reaction

© Copyright Abiopharma. All Rights Reserved
Designed by Alexey Vershinin